Can cannabis help with rheumatoid arthritis?

Preclinical evidence is promising — CBD and THC:CBD combinations reduce joint inflammation and pain in animal models. Human clinical trial data is limited, but observational studies show many RA patients report pain relief and reduced NSAID use. The UK-based PROSPECT trial (CBD in RA) is ongoing. Current evidence does not support cannabis as a first-line RA treatment, but it may be a reasonable adjunct for patients with inadequate pain control.

Is cannabis approved for multiple sclerosis?

Yes — nabiximols (Sativex, a 1:1 THC:CBD oromucosal spray) is approved in over 25 countries including the UK, Canada, and most of Europe for MS-related spasticity that has not responded adequately to other treatments. It is not FDA-approved in the US. Multiple RCTs and a Cochrane review support its efficacy for spasticity, though effects on objective measures are more modest than patient-reported outcomes.

Does cannabis suppress the immune system?

THC has immunosuppressive properties — it reduces T cell proliferation, NK cell activity, and pro-inflammatory cytokine production via CB2 receptor activation. This may be therapeutically useful in autoimmune conditions but raises concerns about infection risk, particularly in patients already on immunosuppressive medications. CBD has a more nuanced immunomodulatory profile and does not appear to cause the same degree of immunosuppression as THC.

Can cannabis help with psoriasis?

Preclinical evidence suggests cannabinoids may reduce keratinocyte proliferation and skin inflammation relevant to psoriasis. CB1 and CB2 receptors are expressed in skin cells, and endocannabinoid signaling regulates epidermal differentiation. However, there are no completed RCTs of cannabinoids specifically for psoriasis. Topical CBD products are widely used anecdotally, but clinical evidence is lacking.

Is it safe to use cannabis if I take immunosuppressant medications?

This requires careful consideration. CBD is a potent inhibitor of CYP3A4 and CYP2C9 enzymes, which metabolize many immunosuppressants including tacrolimus, cyclosporine, and mycophenolate. CBD can significantly increase blood levels of these drugs, raising toxicity risk. THC also interacts with these pathways. Patients on immunosuppressants should consult their physician before using any cannabinoid product.

Research Topic

Autoimmune & Inflammatory Disease

Cannabinoids, immune modulation, and the evidence base

The endocannabinoid system is deeply integrated with immune function — CB2 receptors are densely expressed on immune cells including T cells, B cells, macrophages, and natural killer cells. This positions cannabinoids as plausible immunomodulatory agents, though the clinical evidence varies substantially across autoimmune conditions.

940+ indexed studies Updated May 2026 Reviewed by MD + PhD Evidence Standards

What the Research Shows

Autoimmune diseases arise when the immune system mistakenly attacks the body's own tissues. The endocannabinoid system (ECS) plays a regulatory role in immune homeostasis — CB2 receptor activation generally suppresses pro-inflammatory signaling, reduces cytokine release, and promotes regulatory T cell activity. CBD has demonstrated anti-inflammatory effects across multiple preclinical models of autoimmune disease, including experimental autoimmune encephalomyelitis (EAE, a model of MS), collagen-induced arthritis, and lupus-like nephritis. Clinical evidence is most developed for multiple sclerosis (nabiximols/Sativex is approved in many countries for MS spasticity) and rheumatoid arthritis (CBD and THC:CBD combinations show modest analgesic and anti-inflammatory effects). For conditions like lupus, psoriasis, and inflammatory bowel disease, evidence remains largely preclinical or observational. A key challenge is that THC's immunosuppressive effects, while potentially therapeutic, also raise concerns about infection risk in already immunocompromised patients.

Key Findings

Nabiximols (THC:CBD) reduces MS spasticity

Well-Studied

Multiple RCTs and a Cochrane review confirm significant reductions in patient-reported spasticity scores in MS. Approved in 25+ countries.

CBD reduces joint inflammation in arthritis models

Emerging Research

Preclinical studies consistently show CBD reduces synovial inflammation, cartilage damage, and pro-inflammatory cytokines (TNF-α, IL-6) in collagen-induced arthritis.

CB2 activation suppresses autoimmune neuroinflammation

Emerging Research

CB2 agonists reduce disease severity in EAE models by promoting regulatory T cells and suppressing Th17 responses — a key pathway in MS and other autoimmune conditions.

Cannabis users report symptom relief in lupus and psoriasis

Limited Evidence

Survey and observational data show high rates of self-reported benefit, but controlled clinical trials are lacking for both conditions.

Featured Studies

View all in library

Common Questions

What We Still Don't Know

These are open research questions — areas where the evidence is insufficient or actively contested.

1Can CBD or THC:CBD combinations achieve clinical remission in rheumatoid arthritis?
2What is the optimal cannabinoid ratio and dose for MS spasticity vs. pain vs. bladder dysfunction?
3Does long-term cannabis use affect disease progression in autoimmune conditions?
4Are topical cannabinoids effective for psoriasis and other inflammatory skin conditions?
5How do cannabinoids interact with biologic therapies (TNF inhibitors, IL-17 blockers) used in autoimmune disease?
6Can cannabinoids reduce the need for corticosteroids in lupus flares?

Pain & Inflammation Gut Health & IBD Neuroscience Cannabinoid Pharmacology Cancer & Oncology Full Research Library

Autoimmune & Inflammatory Disease

What the Research Shows

Key Findings

Featured Studies

Cannabinoids for Medical Use: A Systematic Review and Meta-Analysis — Autoimmune Outcomes

Transdermal Cannabidiol Reduces Inflammation and Pain-Related Behaviours in a Rat Model of Arthritis

Cannabidiol as an Emergent Therapeutic Strategy for Lessening the Impact of Inflammation on Oxidative Stress

Patient-Reported Outcomes of Medical Cannabis Use in Rheumatic Diseases

Common Questions

What We Still Don't Know

Autoimmune & Inflammatory Disease

What the Research Shows

Key Findings

Featured Studies

Cannabinoids for Medical Use: A Systematic Review and Meta-Analysis — Autoimmune Outcomes

Transdermal Cannabidiol Reduces Inflammation and Pain-Related Behaviours in a Rat Model of Arthritis

Cannabidiol as an Emergent Therapeutic Strategy for Lessening the Impact of Inflammation on Oxidative Stress

Patient-Reported Outcomes of Medical Cannabis Use in Rheumatic Diseases

Common Questions

What We Still Don't Know

Related Research Topics